启迪药业：控股股东所持5860.7万股股票被司法拍卖 公司控制权将发生变更

Core Viewpoint - The announcement indicates a significant change in the ownership structure of Qidi Pharmaceutical, with Hunan Sailuxian acquiring a substantial stake, leading to a shift in control and governance of the company [1] Group 1: Ownership Changes - Qidi Pharmaceutical received a court ruling that mandates the transfer of 58.607 million shares from Qidi Kefu to Hunan Sailuxian [1] - Following this transfer, Qidi Kefu will no longer hold any shares in Qidi Pharmaceutical, and its associated entity, Huqing Investment, will see its shareholding drop from 63.1514 million shares to 4.5445 million shares [1] - Hunan Sailuxian will hold 58.607 million shares, representing 24.47% of the total share capital of Qidi Pharmaceutical after the transfer [1] Group 2: Impact on Control and Governance - The change in ownership will result in a shift in control of Qidi Pharmaceutical, which is expected to have a significant impact on the company's equity structure and governance [1] - The ownership change does not trigger a mandatory tender offer, indicating that the acquisition process will not require additional offers to other shareholders [1]